New Zealand markets close in 2 hours 36 minutes

Danaher Corporation (DHR)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
249.63-4.83 (-1.90%)
At close: 04:01PM EDT
250.50 +0.87 (+0.35%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close254.46
Open253.33
Bid250.44 x 900
Ask251.40 x 900
Day's range249.33 - 253.33
52-week range221.22 - 283.63
Volume2,402,993
Avg. volume2,667,409
Market cap184.315B
Beta (5Y monthly)0.80
PE ratio (TTM)29.30
EPS (TTM)8.52
Earnings date18 Oct 2023 - 23 Oct 2023
Forward dividend & yield1.08 (0.42%)
Ex-dividend date11 Oct 2023
1y target est280.65
  • Zacks

    Danaher (DHR) Stock Moves -0.3%: What You Should Know

    Danaher (DHR) closed the most recent trading day at $254.46, moving -0.3% from the previous trading session.

  • Zacks

    Danaher (DHR) Stock Sinks As Market Gains: What You Should Know

    Danaher (DHR) closed the most recent trading day at $253.77, moving -0.58% from the previous trading session.

  • Financial Times

    Abcam founder to vote against proposed $5.7bn acquisition by US Danaher

    The founder of UK life sciences company Abcam plans to vote against a proposed $5.7bn acquisition by US group Danaher, pushing instead to replace the board and take back the reins as chief executive. Jonathan Milner, who has a 6.1 per cent stake in the Cambridge-based company, argues the $24-a-share deal materially undervalues Abcam, which creates custom antibodies, among other products, for scientists to use in research. Shares in Abcam were trading at $23.36 before the deal was announced in late August, having risen about 40 per cent after Milner launched a campaign for changes on the board in late May.